New antibody company launched and more funding events…
Want to get this list of recently funded companies and more data? Fill out a quote request to get more info or set up a call (Quote Request Form)
FIG. 1. Recent Biotech Funding Activity.
– Private Funding –
Celaid Therapeutics
💸 Completed series A funding worth a total of 1.2B yen
Uniquity Bio
💸 Launched with $300M capital from Blackstone Life Sciences to Start Phase 2 Clinical Trials in COPD & Asthma with Novel Anti-TSLP Monoclonal Antibody
Lycia Therapeutics
💸 Completed $106.6M series C funding to advance LYTAC extracellular protein degraders pipeline.
Attovia Therapeutics
💸 Raised $105m in Series B financing led by Goldman Sachs Alternatives to advance its lead programs and expand pipeline.
CinDome Pharma
💸 Announced $40M Series B financing extension to support Deudomperidone Ph 2 envision3D trial.
– Post-IPO/Public Funding –
Erasca
🏦 Announced pricing for $160M equity offering with J.P. Morgan and BofA Securities as joint book-running managers.
Cassava Sciences
🏦 Raised $125M from equity financing through exercised warrants to fund simufilam development.
RxSight
🏦 Raised $115M in an oversubscribed public offering.
ADC Therapeutics
🏦 Announced $105M offering and pre-funded warrants.
Reneo Pharmaceuticals
🏦 Proposed merger w/ OnKure which includes $65M private investment in public equity (PIPE) financing.
---
Article History:
RF, DV, DG (05/21/24)
This article is not investment or legal advice.
Comments